Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,489 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Kang BW, Kim WS, Kim C, Jang G, Lee SS, Choi YH, Lee DH, Kim SW, Kim S, Ryu JS, Huh J, Lee JS, Suh C. Kang BW, et al. Among authors: choi yh. Invest New Drugs. 2010 Aug;28(4):516-22. doi: 10.1007/s10637-009-9283-z. Epub 2009 Jun 23. Invest New Drugs. 2010. PMID: 19547918 Clinical Trial.
A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Choi YH, Oh SC, Kim JS, Nam SH, Kim BS, Cho SH, Chung IJ, Song EK, Yim CY, Baek JH, Jeung HC, Hong YS, Yang SH, Kang HJ. Choi YH, et al. Cancer Chemother Pharmacol. 2012 Nov;70(5):665-72. doi: 10.1007/s00280-012-1956-1. Epub 2012 Aug 25. Cancer Chemother Pharmacol. 2012. PMID: 22926638 Clinical Trial.
A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Park I, Ryu MH, Choi YH, Kang HJ, Yook JH, Park YS, Kim HJ, Jung HY, Lee GH, Kim KC, Kim BS, Kang YK. Park I, et al. Among authors: choi yh. Cancer Chemother Pharmacol. 2013 Oct;72(4):815-23. doi: 10.1007/s00280-013-2257-z. Epub 2013 Aug 7. Cancer Chemother Pharmacol. 2013. PMID: 23921575 Clinical Trial.
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13.
Yoo KH, Lee SJ, Cho J, Lee KH, Park KU, Kim KH, Cho EK, Choi YH, Kim HR, Kim HG, Ahn HJ, Lee HY, Yun HJ, Kang JH, Jeong J, Choi MY, Jung SH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Yoo KH, et al. Among authors: choi my, choi yh. Cancer Res Treat. 2019 Apr;51(2):718-726. doi: 10.4143/crt.2018.324. Epub 2018 Sep 3. Cancer Res Treat. 2019. PMID: 30177585 Free PMC article. Clinical Trial.
Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
Park JH, You GL, Ahn MJ, Kim SW, Hong MH, Han JY, Ock CY, Lee JS, Oh IJ, Lee SY, Kim CH, Min YJ, Choi YH, Ryu JS, Park SH, Ahn HK, Shim BY, Lee KH, Lee SY, Kim JS, Yi J, Choi SK, An H, Kang JH. Park JH, et al. Among authors: choi sk, choi yh. J Cancer Res Clin Oncol. 2021 Aug;147(8):2459-2469. doi: 10.1007/s00432-021-03527-4. Epub 2021 Feb 1. J Cancer Res Clin Oncol. 2021. PMID: 33523301
3,489 results